On October 22, 2020 Luminex Corporation (NASDAQ: LMNX) reported that it plans to report results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020 (Press release, Luminex, OCT 22, 2020, View Source [SID1234568882]). A press release announcing the results is scheduled for release after the close of trading on that date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2020 on November 5, 2020, at 5:00 p.m. Eastern Time.

The conference call will be webcast live and may be accessed at Luminex Corporation’s website at View Source Simply log on to the website, go to the About Luminex section and access the Investor Relations link. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

On October 22, 2020 F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, reported that it will present two posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020 (Press release, F-star, OCT 22, 2020, View Source [SID1234568881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters will focus on FS118, F-star’s potentially first-in-class, tetravalent bispecific antibody that simultaneously blocks both the LAG-3 and PD-L1 immunosuppressive pathways. FS118 has preclinically and, in preliminary clinical data, demonstrated potent anti-tumor growth activity as well as a highly differentiated mechanism of action when compared to checkpoint monotherapies alone or in combinations.

Abstracts are available on the SITC (Free SITC Whitepaper) website and the accompanying posters will be available in the Virtual Poster Hall open from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020.

Details of the poster presentations:

Title: A First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, in Patients with Advanced Cancer and Resistance to PD-(L)1 Therapy
Live Q&A: Poster #395 – Wednesday, Nov. 11 from 5:15-5:45 p.m. EST and Friday, Nov. 13 from 4:40-5:10 p.m. EST

Title: FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, Induces LAG-3 Shedding Resulting in Receptor Downregulation by T Cells via a Novel mechanism of Action
Live Q&A: Poster #715 – Wednesday, Nov. 11 from 5:15-5:45 p.m. EST and Friday, Nov. 13 from 4:40-5:10 p.m. EST

On October 22, 2020 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020 before the U.S. financial markets open (Press release, Compugen, OCT 22, 2020, View Source [SID1234568880]). Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link. Following the live audio webcast, a replay will be available on the Company’s website.

On October 22, 2020 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5, at 4:30 p.m. ET to discuss third quarter 2020 financial results and provide a general business update (Press release, BioMarin, OCT 22, 2020, View Source [SID1234568879]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

On October 22, 2020 Johnson & Johnson (NYSE: JNJ) reported that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company’s common stock (Press release, Johnson & Johnson, OCT 22, 2020, View Source;johnson-announces-quarterly-dividend-for-fourth-quarter-2020-301158284.html [SID1234568877]). The dividend is payable on December 8, 2020 to shareholders of record at the close of business on November 24, 2020. The ex-dividend date is November 23, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!